IAMA 006
Alternative Names: IAMA-006Latest Information Update: 24 Sep 2024
At a glance
- Originator Nanjing JSIAMA Biopharmaceuticals
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 09 Sep 2024 Early research in Unspecified in China (Parenteral) prior to September 2024 (Nanjing JSIAMA Biopharmaceuticals pipeline, September 2024)